Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio announced preclinical data supporting its lead ecDNA-directed therapy candidate, BBI-940, a novel oral kinesin degrader targeting ecDNA segregation in cancer cells. The therapy demonstrated potent antitumor activity in breast cancer models, including ER+/HER2- and TNBC-LAR subtypes, and is currently being evaluated in a Phase 1 clinic…